for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lannett Company, Inc.

LCI.N

Latest Trade

4.85USD

Change

-0.08(-1.62%)

Volume

118,974

Today's Range

4.80

 - 

5.08

52 Week Range

4.55

 - 

10.69

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.93
Open
4.90
Volume
118,974
3M AVG Volume
13.47
Today's High
5.08
Today's Low
4.80
52 Week High
10.69
52 Week Low
4.55
Shares Out (MIL)
41.40
Market Cap (MIL)
204.11
Forward P/E
43.51
Dividend (Yield %)
--

Next Event

Q3 2021 Lannett Company Inc Earnings Release

Latest Developments

More

Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026

Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026

Lannett Says Received Feedback From U.S. FDA Regarding Biosimilar Insulin Glargine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lannett Company, Inc.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Industry

Biotechnology & Drugs

Contact Info

9000 State Rd

PHILADELPHIA, PA

19136-1615

United States

+1.215.3339000

https://www.lannett.com/

Executive Leadership

Patrick G. LePore

Independent Chairman of the Board

Timothy C. Crew

Chief Executive Officer, Director

John Kozlowski

Chief Financial Officer, Principal Accounting Officer, Vice President - Finance

John M. Abt

Vice President and Chief Quality and Operations Officer

Maureen M. Cavanaugh

Senior Vice President and Chief Commercial Operations Officer

Key Stats

3.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.7K

2019

0.7K

2020

0.5K

2021(E)

0.5K
EPS (USD)

2018

3.100

2019

2.350

2020

1.070

2021(E)

0.098
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.38
Price To Book (MRQ)
1.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
477.98
LT Debt To Equity (MRQ)
447.54
Return on Investment (TTM)
-24.26
Return on Equity (TTM)
-19.67

Latest News

Latest News

BRIEF-Lannett Anticipates Biosimilar Application For Insulin Glargine To Be Submitted By 2022 End

* LANNETT PROVIDES UPDATE ON CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE, FOLLOWING FDA MEETING

BRIEF-Lannett Posts Q3 Loss Per Share Of $0.43

* LANNETT ANNOUNCES FISCAL 2020 THIRD-QUARTER FINANCIAL RESULTS

BRIEF-Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9

* LANNETT TO MEET WITH FDA REGARDING THE CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE ON JUNE 9

BRIEF-Lannett Begins Marketing Generic Adderall Xr

* LANNETT BEGINS MARKETING GENERIC ADDERALL® XR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Lannett Receives FDA Approval For Dronabinol Capsules

* LANNETT COMPANY INC - RECEIVED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR DRONABINOL CAPSULES USP, 2.5 MG, 5 MG AND 10 MG

BRIEF-Lannett Reports Q3 Adjusted Earnings Per Share $0.80

* LANNETT ANNOUNCES FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS

BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International

* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL

BRIEF-Lannett Appoints Patrick Lepore Chairman Of Board

* LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up